Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
CA Cancer J Clin. 2021 Mar;71(2):176-190. doi: 10.3322/caac.21650. Epub 2020 Nov 9.
The application of genomic profiling assays using plasma circulating tumor DNA (ctDNA) is rapidly evolving in the management of patients with advanced solid tumors. Diverse plasma ctDNA technologies in both commercial and academic laboratories are in routine or emerging use. The increasing integration of such testing to inform treatment decision making by oncology clinicians has complexities and challenges but holds significant potential to substantially improve patient outcomes. In this review, the authors discuss the current role of plasma ctDNA assays in oncology care and provide an overview of ongoing research that may inform real-world clinical applications in the near future.
基于血浆游离循环肿瘤 DNA（ctDNA）的基因组分析检测在晚期实体瘤患者管理中的应用正在迅速发展。商业和学术实验室的各种血浆 ctDNA 技术正在常规使用或开始使用。此类检测在很大程度上提高了患者的治疗效果，但是为了将其整合到肿瘤临床医生的治疗决策中，还存在着复杂性和挑战。在这篇综述中，作者讨论了血浆 ctDNA 检测在肿瘤治疗中的作用，并概述了正在进行的研究，这些研究可能会为近期的实际临床应用提供信息。
